Kamada Ltd. Secures FDA Approval for Houston Plasma Center
Ticker: KMDA · Form: 6-K · Filed: Aug 11, 2025 · CIK: 1567529
| Field | Detail |
|---|---|
| Company | Kamada Ltd (KMDA) |
| Form Type | 6-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, plasma-collection, biotech
TL;DR
Kamada's Houston plasma center got FDA green light, boosting their plasma supply chain.
AI Summary
Kamada Ltd. announced on August 11, 2025, that it has received FDA approval for its plasma collection center located in Houston, Texas. This approval is a significant step for the company's plasma-derived therapeutics business.
Why It Matters
FDA approval of the Houston plasma collection center is crucial for Kamada's ability to source plasma, a key raw material for its plasma-derived therapeutics, potentially impacting its production capacity and revenue.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain new financial information or significant operational changes.
Key Players & Entities
- Kamada Ltd. (company) — Registrant
- FDA (company) — Regulatory body
- Houston, Texas (location) — Location of new plasma collection center
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed by Kamada Ltd. to announce the FDA approval of its plasma collection center in Houston, Texas.
When was the FDA approval for the Houston plasma collection center announced?
The announcement regarding the FDA approval of the Houston plasma collection center was made on August 11, 2025.
What is the significance of the Houston plasma collection center for Kamada Ltd.?
The Houston plasma collection center is important for Kamada's plasma-derived therapeutics business, as it allows for the sourcing of plasma, a key raw material.
Which SEC registration statements is this Form 6-K being incorporated by reference into?
This Form 6-K is being incorporated by reference into Kamada Ltd.'s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, and 333-265866.
Where is Kamada Ltd.'s principal executive office located?
Kamada Ltd.'s principal executive offices are located at 2 Holzman Street Science Park, P.O. Box 4081, Rehovot 7670402, Israel.
Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-08-11 07:00:31
Filing Documents
- ea0252587-6k_kamada.htm (6-K) — 12KB
- ea025258701ex99-1_kamada.htm (EX-99.1) — 14KB
- 0001213900-25-073908.txt ( ) — 27KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720 , 333-207933 , 333-215983 , 333-222891 , 333-233267 and 333-265866 . 1 The following exhibit is attached: 99.1 Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 11, 2025 KAMADA LTD. By: /s/ Nir Livneh Nir Livneh Vice President General Counsel and Corporate Secretary 3 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas 4